Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Company Overview - Arcturus Therapeutics (NASDAQ: ARCT) is actively evaluating LUNAR-CF [ARCT-032] for the treatment of patients with Cystic Fibrosis (CF) [2] Product Development - The company is focused on developing LUNAR-CF, which shows promise in treating CF, indicating a potential advancement in therapeutic options for this condition [2]